{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,30]],"date-time":"2026-08-30T01:51:34Z","timestamp":1788054694936,"version":"build-2784847793"},"reference-count":13,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Drugs"],"published-print":{"date-parts":[[2024,3]]},"DOI":"10.1007\/s40272-023-00608-4","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T13:02:08Z","timestamp":1701954128000},"page":"209-214","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Bosutinib: Pediatric First Approval"],"prefix":"10.1007","volume":"26","author":[{"given":"Sheridan M.","family":"Hoy","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"issue":"2","key":"608_CR1","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1007\/s12185-022-03526-2","volume":"117","author":"H Shima","year":"2023","unstructured":"Shima H, Shimada H. Recent progress in the management of pediatric chronic myeloid leukemia. Int J Hematol. 2023;117(2):182\u20137.","journal-title":"Int J Hematol"},{"issue":"3","key":"608_CR2","doi-asserted-by":"publisher","first-page":"241","DOI":"10.1007\/s40272-021-00446-2","volume":"23","author":"LN Phillips","year":"2021","unstructured":"Phillips LN, Hijiya N. Tyrosine kinase inhibitors and beyond for chronic myeloid leukemia in children. Paediatr Drugs. 2021;23(3):241\u201351.","journal-title":"Paediatr Drugs"},{"issue":"1","key":"608_CR3","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40259-013-0082-x","volume":"28","author":"YY Syed","year":"2014","unstructured":"Syed YY, McCormack PL, Plosker GL. Bosutinib: a review of its use in patients with Philadelphia chromosome-positive chronic myelogenous leukemia. BioDrugs. 2014;28(1):107\u201320.","journal-title":"BioDrugs"},{"key":"608_CR4","unstructured":"Pfizer Inc. BOSULIF\u00ae (bosutinib) tablets and capsules, for oral use: US prescribing information. 2023. https:\/\/www.fda.gov\/. Accessed 13 Oct 2023."},{"key":"608_CR5","unstructured":"Pfizer Inc. BOSULIF\u00ae (bosutinib) tablets, for oral use: US prescribing information. 2012. https:\/\/www.fda.gov\/. Accessed 18 Oct 2023."},{"key":"608_CR6","unstructured":"European Medicines Agency. Bosulif (international non-proprietary name bosutinib): EU assessment report. 2013. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif. Accessed 18 Oct 2023."},{"key":"608_CR7","unstructured":"Pfizer Inc. BOSULIF\u00ae (bosutinib) tablets, for oral use: US prescribing information. 2017. https:\/\/www.fda.gov\/. Accessed 18 Oct 2023."},{"key":"608_CR8","unstructured":"European Medicines Agency. Bosulif (international non-proprietary name bosutinib): EU assessment report. 2018. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/bosulif. Accessed 18 Oct 2023."},{"key":"608_CR9","unstructured":"US Food & Drug Administration. FDA approves bosutinib for pediatric patients with chronic myelogenous leukemia [media release]. 26 Sep 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-approves-bosutinib-pediatric-patients-chronic-myelogenous-leukemia."},{"key":"608_CR10","doi-asserted-by":"publisher","first-page":"274","DOI":"10.12659\/MSMBR.889518","volume":"19","author":"JT Tauer","year":"2013","unstructured":"Tauer JT, Hofbauer LC, Jung R, et al. Micro-osmotic pumps for continuous release of the tyrosine kinase inhibitor bosutinib in juvenile rats and its impact on bone growth. Med Sci Monit Basic Res. 2013;19:274\u20138.","journal-title":"Med Sci Monit Basic Res"},{"issue":"Suppl 1","key":"608_CR11","doi-asserted-by":"publisher","first-page":"2558","DOI":"10.1182\/blood-2021-145709","volume":"138","author":"E Pennesi","year":"2021","unstructured":"Pennesi E, Brivio E, Willemse M. A phase I\/II study of bosutinib in pediatric patients with resistant\/intolerant or newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia, Study ITCC (Innovative Therapies for Children with Cancer European Consortium) 054 and COG (Children\u2019s Oncology Group Consortium) AAML1921: results from the phase I trial in resistant\/intolerant patients [abstract no. 2558]. Blood. 2021;138(Suppl 1):2558\u201360.","journal-title":"Blood"},{"key":"608_CR12","unstructured":"US National Institutes of Health. ClinicalTrials.gov identifier NCT04258943. 2023. https:\/\/clinicaltrials.gov\/study\/NCT04258943. Accessed 30 Oct 2023."},{"issue":"Suppl 5","key":"608_CR13","first-page":"S189","volume":"69","author":"D Keino","year":"2022","unstructured":"Keino D, Tanizawa A, Watanabe A, et al. Analysis of bosutinib for chronic myeloid leukemia in the multicenter, prospective observational study of pediatric chronic myeloid leukemia (PLSG CML-08) [abstract no. EP089\/#1480]. Pediatr Blood Cancer. 2022;69(Suppl 5):S189\u201390.","journal-title":"Pediatr Blood Cancer"}],"container-title":["Pediatric Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00608-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40272-023-00608-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40272-023-00608-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,23]],"date-time":"2024-02-23T15:17:40Z","timestamp":1708701460000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40272-023-00608-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":13,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2024,3]]}},"alternative-id":["608"],"URL":"https:\/\/doi.org\/10.1007\/s40272-023-00608-4","relation":{},"ISSN":["1174-5878","1179-2019"],"issn-type":[{"value":"1174-5878","type":"print"},{"value":"1179-2019","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,7]]},"assertion":[{"value":"7 December 2023","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 December 2023","order":2,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":3,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The original online version of this article was revised to remove the query text from the Abstract.","order":4,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"During the peer review process the manufacturer of the agent under review was offered an opportunity to comment on the article. Changes resulting from any comments received were made by the authors on the basis of scientific completeness and accuracy. Sheridan M. Hoy is a salaried employee of Adis International Ltd\/Springer Nature, and declares no relevant conflicts of interest. All authors contributed to this article and are responsible for its content.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Authorship and Conflict of Interest"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval, Consent to participate, Consent to publish, Availability of data and material, Code availability"}}]}}